Author: Sprave, Tanja; Zamboglou, Constantinos; Verma, Vivek; Nicolay, Nils H; Grosu, Anca-Ligia; Lindenmeier, Jörg; Tscheulin, Dieter K
Title: Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy. Cord-id: bblbp0nd Document date: 2020_9_11
ID: bblbp0nd
Snippet: BACKGROUND Patient-reported quality of life in cancer patients is becoming increasingly important, especially for head-and-neck (H&N) cancers, which are at risk of experiencing severe treatment-related toxicities. Therefore, we sought to characterize the peritherapeutic HRQOL of contemporary patients using the well-validated EQ-5D-5L questionnaire. METHODS All patients receiving radiotherapy for H&N cancers between July 2019 and November 2019 at the University of Freiburg Medical Center who comp
Document: BACKGROUND Patient-reported quality of life in cancer patients is becoming increasingly important, especially for head-and-neck (H&N) cancers, which are at risk of experiencing severe treatment-related toxicities. Therefore, we sought to characterize the peritherapeutic HRQOL of contemporary patients using the well-validated EQ-5D-5L questionnaire. METHODS All patients receiving radiotherapy for H&N cancers between July 2019 and November 2019 at the University of Freiburg Medical Center who completed the first two follow-ups were included. HRQOL was assessed by the validated EQ-5D-5L questionnaire before radiotherapy, after therapy completion, and three and six months following radiotherapy. The changes from baseline to six months for HI and EQ VAS scores were recorded. RESULTS All 49 patients completed the questionnaires at all time points of data collection, yielding 196 total questionnaires. Twenty-eight patients (57.1%) received definitive, 20 (40.8%) adjuvant, and one 2.1%) patient palliative radiotherapy. The mean EQ-5D-5L index score of the overall population before radiotherapy, after radiotherapy, and three and six months following radiotherapy was 0.837 (standard deviation, SD 0.17), 0.828 (SD 0.16), 0.855 (SD 0.15), and 0.856 (SD 0.14) respectively. The respective mean EQ VAS scores were 63.88 (SD 20.72), 63.67 (SD 21.81), 63.67 (SD 21.81), and 65.20 (SD 22.41) respectively. The respective changes of the HI and EQ VAS score over time for this cohort were not significant (Friedman test p=0.273, p=0.618). CONCLUSION Despite the known therapy-related toxicities, no significant permanent deterioration of HRQOL in this cohort was observed. Sub-populations at relatively higher risk of HRQOL deterioration may allow for increased clinical monitoring.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date